Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 10, 2026, 7:40 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 193–216 of 2,287 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Fasted State Clear all

Conditions: Healthy
Interventions: Sumatriptan Succinate Tablets 100 mg, Imitrex® Tablets 100 mg; Drug
Lead sponsor: Mylan Pharmaceuticals Inc; Industry
Eligibility: 18 Years and older
Enrollment: 55 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004
U.S. locations: 1
States / cities: Morgantown, West Virginia

Conditions: Hip Fractures
Interventions: Not listed
Lead sponsor: AO Innovation Translation Center; Other
Eligibility: 70 Years and older
Enrollment: 282 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2020
U.S. locations: 2
States / cities: St Louis, Missouri • New York, New York

Conditions: Anorexia Nervosa, Bulimia Nervosa
Interventions: Imaging, fast, regulated meals; Other · Behavioral
Lead sponsor: University of California, San Diego; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 150 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2014
U.S. locations: 1
States / cities: San Diego, California

Conditions: Healthy
Interventions: metformin hydrochloride 1000 mg tablets; Drug
Lead sponsor: Ranbaxy Laboratories Limited; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006
U.S. locations: 1
States / cities: Las Vegas, Nevada

Conditions: Chronic Stroke
Interventions: Virtual reality based dance group, Active Comparator: Control; Behavioral
Lead sponsor: University of Illinois Chicago; Other
Eligibility: 45 Years to 90 Years
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Healthy
Interventions: Finasteride; Drug
Lead sponsor: Dr. Reddy's Laboratories Limited, India; Industry
Eligibility: 18 Years to 65 Years · Male only
Enrollment: 26 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006
U.S. locations: 1
States / cities: Las Vegas, Nevada

Conditions: Endometrial Neoplasms
Interventions: Time Restricted Eating (TRE) Schedule, Control Schedule; Behavioral
Lead sponsor: University of Utah; Other
Eligibility: 18 Years and older · Female only
Enrollment: 39 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Fabry Disease
Interventions: A (migalastat), B (migalastat), C (migalastat), D (migalastat), E (migalastat); Drug
Lead sponsor: Amicus Therapeutics; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Pain
Interventions: 14C-VX-993; Drug
Lead sponsor: Vertex Pharmaceuticals Incorporated; Industry
Eligibility: 18 Years to 55 Years · Male only
Enrollment: 8 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025
U.S. locations: 1
States / cities: Lincoln, Nebraska

Conditions: Healthy, Natriuretic Peptides, Metabolic Syndrome
Interventions: Study diet, Glucose Challenge; Dietary Supplement · Other
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 18 Years to 40 Years
Enrollment: 81 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Schizophrenia, Schizoaffective Disorder, Brief Psychotic Disorder, Schizophreniform Disorder, Unspecified Schizophrenia Spectrum and Other Psychotic Disorder
Interventions: Exercise Intervention- PACE-Life; Behavioral
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 18 Years to 65 Years
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 2
States / cities: Chapel Hill, North Carolina • Raleigh, North Carolina

Conditions: Obesity, Overweight, Overnutrition, Nutrition Disorders, Signs and Symptoms
Interventions: Intervention Program; Behavioral
Lead sponsor: Duke University; Other
Eligibility: 21 Years and older
Enrollment: 443 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2023
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Small Bowel Bacterial Overgrowth, Gastrointestinal Diseases, Stomach Diseases, Digestive System Diseases
Interventions: Xifaxan, SmartPill, Lactulose hydrogen breath test (H_2BT); Drug · Device · Procedure
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 70 Years
Enrollment: 17 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2010
U.S. locations: 1
States / cities: Scottsdale, Arizona

Conditions: Cardiovascular Disease
Interventions: Observation of SAA on apoB containing lipoproteins; Other
Lead sponsor: Lisa Tannock; Other
Eligibility: 40 Years and older
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 1
States / cities: Lexington, Kentucky

Conditions: Gestational Diabetes, Pregnancy Related
Interventions: Insulin; Drug
Lead sponsor: Thomas Jefferson University; Other
Eligibility: 18 Years and older · Female only
Enrollment: 430 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2026
U.S. locations: 2
States / cities: Rochester, New York • Philadelphia, Pennsylvania

Conditions: Healthy, Renal Impairment
Interventions: Calderasib; Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 34 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 2
States / cities: Orlando, Florida • Chicago, Illinois

Conditions: Prostate Cancer
Interventions: Abiraterone acetate; Drug
Lead sponsor: Cougar Biotechnology, Inc.; Industry
Eligibility: 40 Years to 80 Years · Male only
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: Orlando, Florida

Conditions: Childhood Cancer Survivors
Interventions: prolonged overnight fasting, usual care; Other
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2027
U.S. locations: 1
States / cities: New York, New York

Conditions: Postpartum Weight Retention, Overweight and Obesity
Interventions: Early Time-Restricted Eating (eTRE), Control; Behavioral
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 18 Years and older · Female only
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Type 2 Diabetes Mellitus
Interventions: Exenatide, Glargine Insulin; Drug
Lead sponsor: Joslin Diabetes Center; Other
Eligibility: 18 Years to 75 Years
Enrollment: 72 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2010
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Advanced Gastric Cancer
Interventions: Nivolumab, Ipilimumab, Relatlimab, BMS-986205, Rucaparib; Biological · Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 190 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2022
U.S. locations: 16
States / cities: Phoenix, Arizona • Duarte, California • Aurora, Colorado + 13 more

Conditions: Chronic Myelogenous Leukemia, Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Interventions: Asciminib single agent, Imatinib, Nilotinib, Bosutinib, Dasatinib, Asciminib single agent pediatric formulation; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 7 Years to 100 Years
Enrollment: 347 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2030
U.S. locations: 9
States / cities: Ann Arbor, Michigan • St Louis, Missouri • New York, New York + 6 more

Conditions: Neoplasms, Pancreatic
Interventions: GSK3145095, Pembrolizumab; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 6
States / cities: Indianapolis, Indiana • New York, New York • Philadelphia, Pennsylvania + 1 more

Conditions: Chronic Urticaria
Interventions: Stress intervention; Behavioral
Lead sponsor: University of Mississippi Medical Center; Other
Eligibility: 18 Years to 64 Years
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010
U.S. locations: 1
States / cities: Jackson, Mississippi

Search by objective public record fields.

Fasting Study of Sumatriptan Succinate Tablets 100 mg to Imitrex® Tablets 100 mg

Geriatric Fracture Centers - Evaluation of a Geriatric Co-management Program

Neurobiology of Anorexia and Bulimia Nervosa

Bioequivalence Study of Metformin Hydrochloride 1000mg Tablets Under Fasting Conditions

Active Balance and Cardio Care Intervention on Physical and Cardiovascular Health in People With Chronic Stroke

Bioequivalence Study of Two Finasteride 5 mg Tablet Formulations Under Non-Fasting Conditions

Time Restricted Eating (TRE) Among Native Hawaiian/Pacific Islander Women at Risk for Endometrial Cancer

Migalastat Food Effect Study

A Study to Evaluate How the Body Processes 14C-VX-993 After a Single Oral Dose

Racial Differences in the Natriuretic Peptide Response to Glucose Challenge

Targeting Physical Health in Schizophrenia: Physical Activity Can Enhance Life

Balance: A Pragmatic Trial of a Digital Health Intervention to Prevent Weight Gain in Primary Care

Transit Time and Bacterial Overgrowth Using SmartPill Capsule

The Association of SAA With Apolipoprotein B Affects Cardiovascular Risk

Strict Versus Permissive Thresholds for Initiation of Pharmacotherapy in Gestational Diabetes

A Clinical Study of Calderasib (MK-1084) in Participants With Renal Impairment (MK-1084-010)

A Study to Assess the Effect of Abiraterone Acetate in Male Participants With Mild or Moderate Hepatic Impairment Compared to Matched Control Participants With Normal Hepatic Function

Overnight Fasting After Completion of Therapy: The OnFACT Study

Time-restricted Eating for Postpartum Weight Loss

The Effect of Exenatide Compared to Lantus Insulin on Vascular Function in Type 2 Diabetes

A Study to Test Combination Treatments in Participants With Advanced Gastric Cancer

Asciminib Roll-over Study

First-time-in-human (FTIH) Study of GSK3145095 Alone and in Combination With Other Anticancer Agents in Adults With Advanced Solid Tumors

Stress Intervention for Chronic Urticaria